Janar Sathananthan, Ole De Backer, and Michael Reardon dive into the newest findings on TAVR from the late-breaking ACURATE IDE trial.

Though X (formerly Twitter) was once a place many cardiologists found community and opportunity, many are jumping ship.

An increased risk of cardiovascular disease may be present as early as 30 years before a type 2 diabetes diagnosis is made, ...

Written to offer advice where formal guidelines fall short, the document urges a balance between bleeding and ischemic risk.

The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.

Much remains to learn about this anatomical finding, seen in about one-third of adults, and how it may affect stroke risk.

These data should help reassure those concerned with the risks of educating physicians through live cases at medical meetings ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

Investigators saw more deaths in patients with severe TR after repeat mitral valve procedures; what to do about it is unclear ...

The study was stopped early to allow all patients with advanced PAH the option for treatment with the activin signaling ...

There remains a need to identify patients who will derive benefits from adjunctive techniques on top of pulmonary vein ...

A multistate model that enables real-time risk recalculations may help improve risk stratification for prediction of ...